Humanigen Inc.

Humanigen Inc.: Humanigen is developing Lenzilumab, an anti-GM-CSF therapy. Multiple ongoing trials for the treatment of COVID-related ARDS including the ACTIV-5 trial conducted by the NIH. Lenz originally developed to stop cytokine storm in CAR-T patients.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase III
Disease Space
Anti-inflammatory, COVID-19, Infectious Disease, Oncology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Antibodies
Website:
Address:
533 Airport Blvd
Suite 400
Burlingame, CA 94010
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Cameron Durrant, MD
Humanigen Inc., Chairman, CEO and Interim CFO
Dr. Cameron Durrant serves as the Chairman and Chief Executive Officer at Humanigen. He also served as a Board Member at Alcyone Lifesciences. He is an accomplished pharmaceuticals and biotech entrepreneur, marketer, financing, business and corporate development professional with a strong medical base. He has served as chairman and director on the boards of numerous companies, and operated as CEO or interim CEO for four venture-backed companies. In other assignments, he has been a senior executive at Johnson and Johnson, Pharmacia Corporation, GSK and Merck,. He has served as the founding investor, Chairman and CEO of publicly-traded PediaRX (acquired by Apricus Biosciences, a NASDAQ company), Executive Chairman of publicly traded Anavez, CEO of PediaMed Pharmaceuticals (acquired by Connetics Corporation and also Tiber Labs), Chairman of Pressure Point (now with an FDA-cleared, marketed medical device), founding director of Bexion Pharmaceuticals (now with a Phase I, novel lipid/protein nanotech oncology therapeutic/imaging agent), board member of Topaz Pharmaceuticals (acquired by Sanofi-Pasteur), board member of PDS Biotechnology Corporation and founder investor in Prism Pharmaceuticals (acquired by Baxter). He has been involved in 5 exits, ranging from a 2-9x return. Dr. Durrant has been an advisor to Microsoft Corporation, Aprecia Pharmaceuticals, Pilgrim Software (acquired by a private equity group), PathXL and Saxa Private Equity Partners. He has also been involved in creating companies around targeted early-stage technologies with Cincinnati Children's Hospital and assisted numerous private equity groups in their diligence efforts, leading to successful deal closure. He has raised significant capital in VC, private equity, angel and high net worth financings. Durrant brings to the biotech industry experience from leadership roles at ECR Pharmaceuticals, PediatRx, PediaMed Pharmaceuticals, Taran Pharma, Johnson & Johnson ($JNJ), Pharmacia, GlaxoSmithKline and Merck ($MRK). He is a Co-Founder and serves as a Board Member at Bexion Pharmaceuticals.
Richard Brown
Humanigen Inc., Director of Investor Relations
Richard is with Humanigen, serving as Director of Investor Relations.
Timothy Edward Morris
Humanigen Inc., CFO/COO
Mr. Morris served as Chief Financial Officer fro 2014-2020. Previously, Mr. Morris served as a Chief Financial Officer, Senior Vice President Finance and Global Corporate Development of VIVUS, Inc. from November 2004 to December 2013. At VIVUS Mr. Morris oversaw finance, corporate development, IT, human resources, legal, and investor relations functions. Prior to VIVUS, Mr. Morris was CFO, Senior Vice President Finance, Manufacturing and Administration from September 2001 to November 2004, and was a member of the Office of the President from August 2004 to November 2004 for Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development, acquisition, and marketing of pharmaceutical products. Mr. Morris graduated cum laude with a BS in Business with emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant.

Top 10 Holders of Humanigen Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Valiant Capital Management LP 16.93 7,074,220 127.62 13F 12/31/20
Black Horse Capital Management LLC 4.75 2,785,258 50.25 Stakes 9/18/20
The Vanguard Group, Inc. 4.38 1,829,254 33.00 Funds 3/31/21
Vanguard Group, Inc. (Subfiler) 3.81 1,593,293 28.74 13F 12/31/20
Think Investments LP 3.20 1,337,808 24.13 13F 12/31/20
BlackRock Institutional Trust Co. NA 1.71 712,710 12.86 13F 12/31/20
Citadel LP 1.48 618,419 11.16 13F 12/31/20
Geode Capital Management LLC 0.85 353,828 6.38 13F 12/31/20
Charles Schwab Investment Management, Inc. 0.45 186,843 3.37 13F 12/31/20
tru Independence LLC 0.37 154,270 2.78 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.